查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
白介素 6 (IL-6) 抑制劑市場、份額、規模、趨勢、行業分析報告：按藥物類型；按疾病類型；按分銷管道；按地區；細分市場預測，2023-2032 年
市場調查報告書
商品編碼
1346913

白介素 6 (IL-6) 抑制劑市場、份額、規模、趨勢、行業分析報告：按藥物類型；按疾病類型；按分銷管道；按地區；細分市場預測，2023-2032 年

Interleukin-6 (IL-6) Inhibitors Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Tocilizumab, Siltuximab, and Sylvant); By Disease Type; By Distribution Channel; By Region; Segment Forecast, 2023-2032
出版日期: | 出版商: Polaris Market Research | 英文 118 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的最新研究，白細胞介素 6 (IL-6) 抑制劑的全球市場預計到 2032 年將達到 863.1 億美元。 該報告提供了對當前市場動態的詳細見解，並對未來市場成長進行了分析。

白細胞介素 6 (IL-6) 抑制劑的日益普及促使公司和許多組織投資於研發。 例如，2022年12月，靜脈注射（IV）托珠單抗（Actemra）被美國食品藥物管理局（FDA）核准用於特殊情況下住院病患的COVID-19管理。 由於Roche的批准，托珠單抗是 FDA 批准的第一個用於治療大流行病毒的單株抗體。 此外，2021年9月，Hetero的托珠單抗生物相似藥獲得了印度藥品監管總局（DCGI）的上市批准，托珠單抗是一種用於住院患者的COVID-19治療藥物。 多個組織和行業參與者的貢獻正在顯著推動全球市場的成長。

自體免疫疾病和發炎性疾病的日益普及預計將刺激全球市場的發展。 IL-6在多種自體免疫和發炎疾病的發展中發揮重要作用，包括類風濕性關節炎、幼年特發性關節炎、Castleman疾病和細胞激素釋放症候群(CRS)。 這些疾病在全球範圍內的盛行率不斷上升，推動了對 IL-6 抑制劑等有效治療藥物的需求。

慢性發炎性疾病盛行率的增加是推動全球市場成長的主要因素之一。 類風濕性關節炎、幼年特發性關節炎和卡斯爾曼氏症等慢性發炎性疾病在全世界不斷增加。 例如，在北美和歐洲，估計每 10,000 名兒童中有 4 至 16 名患有幼年特發性關節炎。 IL-6 抑制劑已被證明可以有效控制這些疾病的症狀和進展，從而推動了對 IL-6 抑制劑的需求。 為此，正在開發世界市場。

白細胞介素 6 (IL-6) 抑制劑市場報告重點

托珠單抗預計將在 2022 年創下最大的市場份額，因為它是首批獲批並進入市場的 IL-6 抑制劑之一。

由於類風濕性關節炎的盛行率相對較高，預計將佔全球市場最大的銷售份額

專賣零售店是IL-6抑制劑的重要通路，2022年佔全球銷售額的最大份額

由於公司和組織臨床試驗的增加以及產業研發的激增，北美將在 2022 年佔據最大份額。

目錄

第一章簡介

第 2 章執行摘要

第三章研究方法

第 4 章全球白血球介素 6 (IL-6) 抑制劑市場洞察

  • 白血球介素 6 (IL-6) 抑制劑市場 - 通路概況
  • 白介素6（IL-6）抑制劑的市場動態
    • 推動者和機會
      • 類風濕性關節炎 (RA) 盛行率不斷上升
      • 熱門白細胞介素 6 抑制劑
    • 抑制因素和挑戰
      • 開發成本高
  • PESTEL 分析
  • 白介素 6 (IL-6) 抑制劑市場通路趨勢
  • 價值鏈分析
  • COVID-19 感染的影響分析

第五章依疾病類型劃分的全球白血球介素 6 (IL-6) 抑制劑市場

  • 主要發現
  • 簡介
  • 類風濕性關節炎
  • 卡斯爾曼病
  • 癌症（腎臟癌、攝護腺癌）
  • 動脈炎

第 6 章全球白血球介素 6 (IL-6) 抑制劑市場（以藥物類型）

  • 主要發現
  • 簡介
  • 托珠單抗
  • 司妥昔單抗
  • 西爾萬特

第 7 章全球白血球介素 6 (IL-6) 抑制劑市場（依通路）

  • 主要發現
  • 簡介
  • 零售藥局
  • 醫院藥房
  • 專業藥房
  • 網路藥局
  • 其他銷售管道

第 8 章全球白血球介素 6 (IL-6) 抑制劑市場（按地區）

  • 主要發現
  • 簡介
    • 白細胞介素 6 (IL-6) 抑制劑市場評估，地區，2019-2032 年
  • 白細胞介素 6 (IL-6) 抑制劑市場 - 北美
    • 北美：白細胞介素 6 (IL-6) 抑制劑市場，依疾病類型劃分，2019-2032 年
    • 北美：2019-2032 年白介素 6 (IL-6) 抑制劑市場（依分銷管道）
    • 北美：2019-2032 年白介素 6 (IL-6) 抑制劑市場（依藥物類型）
    • 白細胞介素 6 (IL-6) 抑制劑市場 - 美國
    • 白細胞介素 6 (IL-6) 抑制劑市場 - 加拿大
  • 白細胞介素 6 (IL-6) 抑制劑市場 - 歐洲
    • 歐洲：白細胞介素 6 (IL-6) 抑制劑市場，依疾病類型劃分，2019-2032 年
    • 歐洲：白血球介素 6 (IL-6) 抑制劑市場（依通路），2019-2032 年
    • 歐洲：白細胞介素 6 (IL-6) 抑制劑市場（依藥物類型），2019-2032 年
    • 白血球介素 6 (IL-6) 抑制劑市場 - 英國
    • 白血球介素 6 (IL-6) 抑制劑市場 - 法國
    • 白細胞介素 6 (IL-6) 抑制劑市場 - 德國
    • 白細胞介素 6 (IL-6) 抑制劑市場 - 義大利
    • 白細胞介素 6 (IL-6) 抑制劑市場 - 西班牙
    • 白細胞介素 6 (IL-6) 抑制劑市場 - 荷蘭
    • 白細胞介素 6 (IL-6) 抑制劑市場 - 俄羅斯
  • 白血球介素 6 (IL-6) 抑制劑市場 - 亞太地區
    • 亞太地區：白血球介素 6 (IL-6) 抑制劑市場（依疾病類型），2019-2032 年
    • 亞太地區：白血球介素 6 (IL-6) 抑制劑市場（依通路），2019-2032 年
    • 亞太地區：白血球介素 6 (IL-6) 抑制劑市場（依藥物類型），2019-2032 年
    • 白血球介素 6 (IL-6) 抑制劑市場 - 中國
    • 白細胞介素 6 (IL-6) 抑制劑市場 - 印度
    • 白血球介素 6 (IL-6) 抑制劑市場 - 馬來西亞
    • 白血球介素 6 (IL-6) 抑制劑市場 - 日本
    • 白細胞介素 6 (IL-6) 抑制劑市場 - 印尼
    • 白血球介素 6 (IL-6) 抑制劑市場 - 韓國
  • 白細胞介素 6 (IL-6) 抑制劑市場 - 中東和非洲
    • 中東和非洲：白細胞介素 6 (IL-6) 抑制劑市場（按疾病類型），2019-2032 年
    • 中東和非洲：白細胞介素 6 (IL-6) 抑制劑市場（按分銷管道），2019-2032 年
    • 中東和非洲：白細胞介素 6 (IL-6) 抑制劑市場（按藥物類型），2019-2032 年
    • 白細胞介素 6 (IL-6) 抑制劑市場 - 沙烏地阿拉伯
    • 白血球介素 6 (IL-6) 抑制劑市場 - 阿拉伯聯合大公國
    • 白血球介素 6 (IL-6) 抑制劑市場 - 以色列
    • 白血球介素 6 (IL-6) 抑制劑市場 – 南非
  • 白細胞介素 6 (IL-6) 抑制劑市場 - 拉丁美洲
    • 拉丁美洲：白細胞介素 6 (IL-6) 抑制劑市場，依疾病類型劃分，2019-2032 年
    • 拉丁美洲：白細胞介素 6 (IL-6) 抑制劑市場，依分銷管道劃分，2019-2032 年
    • 拉丁美洲：白介素 6 (IL-6) 抑制劑市場（按藥物類型），2019-2032 年
    • 白細胞介素 6 (IL-6) 抑制劑市場 - 墨西哥
    • 白細胞介素 6 (IL-6) 抑制劑市場 - 巴西
    • 白細胞介素 6 (IL-6) 抑制劑市場 - 阿根廷

第九章競爭態勢

  • 擴張與收購分析
    • 放大
    • 收購
  • 夥伴關係/協作/協議/揭露

第十章公司簡介

  • AbbVie
  • AstraZeneca
  • Bausch Health
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson and Johnson Services
  • Novartis
  • Regeneron Pharmaceuticals
  • Roche
  • Teva Pharmaceutical
Product Code: PM3720

The global interleukin-6 (IL-6) inhibitors market size is expected to reach USD 86.31 billion by 2032, according to a new study by Polaris Market Research. The report "Interleukin-6 (IL-6) Inhibitors Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Tocilizumab, Siltuximab, and Sylvant); By Disease Type; By Distribution Channel; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The growing popularity of interleukin-6 (IL-6) inhibitors has led businesses and many organizations to invest in research and development. For example, in December 2022, Tocilizumab (Actemra), administered intravenously (IV), was authorized by the US Food and Drug Administration (FDA) for the management of COVID-19 in hospitalized individuals receiving extra care. Tocilizumab was the first monoclonal antibody approved by the FDA to treat the pandemic virus, thanks to the approval given to Roche. In addition to this, in September 2021, Hetero received approval from the Drug Controller General of India (DCGI) for the sale of a biosimilar version of Tocilizumab, a COVID-19 medication for hospitalized people. Contributions of several organizations and industry participants are significantly augmenting the market's growth worldwide.

The increasing prevalence of autoimmune and inflammatory diseases will likely spur the global market's development. IL-6 is critical in the pathogenesis of various autoimmune and inflammatory diseases, such as rheumatoid arthritis, juvenile idiopathic arthritis, Castleman disease, and cytokine release syndrome (CRS). The rising prevalence of these conditions worldwide drives the demand for effective therapies like IL-6 inhibitors.

The increasing prevalence of chronic inflammatory conditions is one of the primary factors likely to enhance the market's growth globally. Chronic inflammatory conditions such as rheumatoid arthritis, juvenile idiopathic arthritis, and Castleman disease are rising globally. For example, as per the estimates, 4 to 16 out of every 10,000 kids in North America and Europe will have juvenile idiopathic arthritis. IL-6 inhibitors have shown efficacy in managing the symptoms and progression of these conditions, driving the demand for IL-6 inhibitors. Henceforth, this heightens the development in the global market.

Interleukin-6 (IL-6) Inhibitors Market Report Highlights

Tocilizumab drug is anticipated to record the largest market share in the year of 2022 as it was one of the first IL-6 inhibitors to receive regulatory approval and enter the market

Rheumatoid arthritis disease type is expected to garner the largest revenue in the global market due to relatively high prevalence of the diseases

Specialty retailers segment is accounting largest market share of the global revenue in the fiscal year of 2022 as these are a key distribution channel for IL-6 inhibitors

North America held the largest share as of 2022 due to increasing clinical trials among companies and organizations and surging research and development in the industry

The global players include: AbbVie, inc., AstraZeneca, Bausch Health, Johnson and Johnson Services, Novartis, GlaxoSmithKline, Eli Lilly, Teva Pharmaceutical, Regeneron Pharmaceuticals, Roche, and others

Polaris Market Research has segmented the Interleukin-6 (IL-6) Inhibitors market report based on drug type, disease type, and distribution channel, and region:

Interleukin-6 (IL-6) Inhibitors, Type Outlook (Revenue - USD Billion, 2019-2032)

  • Tocilizumab
  • Siltuximab
  • Sylvant

Interleukin-6 (IL-6) Inhibitors, Disease Type Outlook (Revenue - USD Billion, 2019-2032)

  • Rheumatoid Arthritis
  • Castleman's disease
  • Cancers (Renal cancer, Prostate cancer)
  • Arteritis

Interleukin-6 (IL-6) Inhibitors, Distribution Channel Outlook (Revenue - USD Billion, 2019-2032)

  • Retail Pharmacies
  • Hospital pharmacies
  • Specialty pharmacies
  • Online pharmacies
  • Other Sales Channel

Interleukin-6 (IL-6) Inhibitors, Regional Outlook (Revenue - USD Billion, 2019-2032)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Netherlands
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Indonesia
    • Malaysia
  • Latin America
    • Argentina
    • Brazil
    • Mexico
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Israel
    • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Interleukin-6 (IL-6) Inhibitors Market Insights

  • 4.1. Interleukin-6 (IL-6) Inhibitors Market - Distribution Channel Snapshot
  • 4.2. Interleukin-6 (IL-6) Inhibitors Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing prevalence of rheumatoid arthritis (RA)
      • 4.2.1.2. High popularity of interleukin-6 inhibitor
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High development cost
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Interleukin-6 (IL-6) Inhibitors Market Distribution Channel Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Interleukin-6 (IL-6) Inhibitors Market, by Disease Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • 5.3. Rheumatoid Arthritis
    • 5.3.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Rheumatoid Arthritis, by Region, 2019-2032 (USD Billion)
  • 5.4. Castleman's disease
    • 5.4.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Castleman's disease, by Region, 2019-2032 (USD Billion)
  • 5.5. Cancers (Renal cancer, Prostate cancer)
    • 5.5.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Cancers (Renal cancer, Prostate cancer), by Region, 2019-2032 (USD Billion)
  • 5.6. Arteritis
    • 5.6.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Arteritis, by Region, 2019-2032 (USD Billion)

6. Global Interleukin-6 (IL-6) Inhibitors Market, by Drug Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • 6.3. Tocilizumab
    • 6.3.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Tocilizumab, by Region, 2019-2032 (USD Billion)
  • 6.4. Siltuximab
    • 6.4.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Siltuximab, by Region, 2019-2032 (USD Billion)
  • 6.5. Sylvant
    • 6.5.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Sylvant, by Region, 2019-2032 (USD Billion)

7. Global Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 7.3. Retail Pharmacies
    • 7.3.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Retail Pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.4. Hospital pharmacies
    • 7.4.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Hospital pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.5. Specialty pharmacies
    • 7.5.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Specialty pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.6. Online pharmacies
    • 7.6.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Online pharmacies, By Region, 2019-2032 (USD Billion)
  • 7.7. Other sales channel
    • 7.7.1. Global Interleukin-6 (IL-6) Inhibitors Market, by Other sales channel, By Region, 2019-2032 (USD Billion)

8. Global Interleukin-6 (IL-6) Inhibitors Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Interleukin-6 (IL-6) Inhibitors Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Interleukin-6 (IL-6) Inhibitors Market - North America
    • 8.3.1. North America: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.3.2. North America: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.3.3. North America: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.3.4. Interleukin-6 (IL-6) Inhibitors Market - U.S.
      • 8.3.4.1. U.S.: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.3.5. Interleukin-6 (IL-6) Inhibitors Market - Canada
      • 8.3.5.1. Canada: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.4. Interleukin-6 (IL-6) Inhibitors Market - Europe
    • 8.4.1. Europe: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.4. Interleukin-6 (IL-6) Inhibitors Market - UK
      • 8.4.4.1. UK: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.5. Interleukin-6 (IL-6) Inhibitors Market - France
      • 8.4.5.1. France: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.6. Interleukin-6 (IL-6) Inhibitors Market - Germany
      • 8.4.6.1. Germany: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.7. Interleukin-6 (IL-6) Inhibitors Market - Italy
      • 8.4.7.1. Italy: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.8. Interleukin-6 (IL-6) Inhibitors Market - Spain
      • 8.4.8.1. Spain: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.9. Interleukin-6 (IL-6) Inhibitors Market - Netherlands
      • 8.4.9.1. Netherlands: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.4.10. Interleukin-6 (IL-6) Inhibitors Market - Russia
      • 8.4.10.1. Russia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.5. Interleukin-6 (IL-6) Inhibitors Market - Asia Pacific
    • 8.5.1. Asia Pacific: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.4. Interleukin-6 (IL-6) Inhibitors Market - China
      • 8.5.4.1. China: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.5. Interleukin-6 (IL-6) Inhibitors Market - India
      • 8.5.5.1. India: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.6. Interleukin-6 (IL-6) Inhibitors Market - Malaysia
      • 8.5.6.1. Malaysia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.7. Interleukin-6 (IL-6) Inhibitors Market - Japan
      • 8.5.7.1. Japan: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.8. Interleukin-6 (IL-6) Inhibitors Market - Indonesia
      • 8.5.8.1. Indonesia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.5.9. Interleukin-6 (IL-6) Inhibitors Market - South Korea
      • 8.5.9.1. South Korea: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.6. Interleukin-6 (IL-6) Inhibitors Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.4. Interleukin-6 (IL-6) Inhibitors Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.5. Interleukin-6 (IL-6) Inhibitors Market - UAE
      • 8.6.5.1. UAE: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.6. Interleukin-6 (IL-6) Inhibitors Market - Israel
      • 8.6.6.1. Israel: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.6.7. Interleukin-6 (IL-6) Inhibitors Market - South Africa
      • 8.6.7.1. South Africa: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • 8.7. Interleukin-6 (IL-6) Inhibitors Market - Latin America
    • 8.7.1. Latin America: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.7.4. Interleukin-6 (IL-6) Inhibitors Market - Mexico
      • 8.7.4.1. Mexico: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.7.5. Interleukin-6 (IL-6) Inhibitors Market - Brazil
      • 8.7.5.1. Brazil: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
    • 8.7.6. Interleukin-6 (IL-6) Inhibitors Market - Argentina
      • 8.7.6.1. Argentina: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. AbbVie
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. AstraZeneca
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Bausch Health
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Eli Lilly
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. GlaxoSmithKline
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Johnson and Johnson Services
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Novartis
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Regeneron Pharmaceuticals
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Roche
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Teva Pharmaceutical
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development

List of Tables

  • Table 1 Global Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 2 Global Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 3 Global Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 4 Interleukin-6 (IL-6) Inhibitors Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 6 North America: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 7 North America: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 8 U.S.: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 9 U.S.: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 10 U.S.: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 11 Canada: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 12 Canada: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 13 Canada: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 14 Europe: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 15 Europe: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 16 Europe: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 17 UK: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 18 UK: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 19 UK: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 20 France: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 21 France: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 22 France: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 23 Germany: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 24 Germany: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 25 Germany: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 26 Italy: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 27 Italy: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 28 Italy: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 29 Spain: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 30 Spain: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 31 Spain: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 35 Russia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 36 Russia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 37 Russia: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 41 China: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 42 China: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 43 China: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 44 India: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 45 India: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 46 India: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 50 Japan: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 51 Japan: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 52 Japan: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 56 South Korea: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 57 South Korea: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 58 South Korea: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 65 UAE: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 66 UAE: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 67 UAE: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 68 Israel: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 69 Israel: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 70 Israel: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 71 South Africa: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 72 South Africa: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 73 South Africa: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 74 Latin America: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 75 Latin America: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 76 Latin America: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 77 Mexico: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 78 Mexico: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 79 Mexico: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 80 Brazil: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 81 Brazil: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 82 Brazil: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 83 Argentina: Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2019-2032 (USD Billion)
  • Table 84 Argentina: Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2019-2032 (USD Billion)
  • Table 85 Argentina: Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Interleukin-6 (IL-6) Inhibitors Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Drug Type
  • Figure 7. Global Interleukin-6 (IL-6) Inhibitors Market, by Drug Type, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Disease Type
  • Figure 9. Global Interleukin-6 (IL-6) Inhibitors Market, by Disease Type, 2022 & 2032 (USD Billion)
  • Figure 10. Market by Distribution Channel
  • Figure 11. Global Interleukin-6 (IL-6) Inhibitors Market, by Distribution Channel, 2022 & 2032 (USD Billion)
  • Figure 12. Interleukin-6 (IL-6) Inhibitors Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Interleukin-6 (IL-6) Inhibitors Market